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Abstract
Background: We conducted a randomized controlled trial of
EpxDiabetes, a novel digital health intervention as an adjunct
therapy to reduce HbA1c and fasting blood glucose (FBG) among
patients with type 2 diabetes mellitus (T2DM). In addition, we
examined the effect of social determinants of health on our system.
Methods: Sixty-five (n = 65) patients were randomized at a
primary care clinic. Self-reported FBG data were collected by
EpxDiabetes automated phone calls or text messages. Only in-
tervention group responses were shared with providers, facili-
tating follow-up and bidirectional communication. DHbA1c and
DFBG were analyzed after 6 months.
Results: There was an absolute HbA1c reduction of 0.69% in
the intervention group (95% confidence interval [CI], -1.41 to
0.02) and an absolute reduction of 0.03% in the control group
(95% CI, -0.88 to 0.82). For those with baseline HbA1c >8%,
HbA1c decreased significantly by 1.17% in the intervention
group (95% CI, -1.90 to -0.44), and decreased by 0.02% in the
control group (95% CI, -0.99 to 0.94). FBG decreased in the
intervention group by 21.6mg/dL (95% CI, -37.56 to -5.639),
and increased 13.0mg/dL in the control group (95% CI, -47.67
to 73.69). Engagement (proportion responding to ‡25% of texts
or calls over 4 weeks) was 58% for the intervention group (95%
CI, 0.373–0.627) and 48% for the control group (95% CI,
0.296–0.621). Smoking, number of comorbidities, and response
rate were significant predictors of DHbA1c.
Conclusions: EpxDiabetes helps to reduce HbA1c in patients
with uncontrolled T2DM and fosters patient–provider com-
munication; it has definite merit as an adjunct therapy in
diabetes management. Future work will focus on improving
the acceptability of the system and implementation on a larger
scale trial.
Keywords: telemedicine, diabetes, glycemic control, self-
monitoring, digital health, e-health
Introduction
D
iabetes is estimated to affect 30.3 million people
(9.4% of the population) in the United States.1 Long-
term glycemic control can decrease the incidence of
organ damage from microvascular and macro-
vascular complications.2 The 2010 National Health and Nu-
trition Examination Survey estimates that 30% of adults with
diabetes have not met target HbA1c levels.
3 In addition, 63.9%
of adults with type 2 diabetes mellitus (T2DM) do not meet
American Diabetes Association (ADA) recommended self-
monitoring frequencies.4 Generating new methods to promote
self-blood glucose measurements and facilitate patient–
provider assessment has the potential to positively impact
blood glucose control in large populations.
Previous studies indicate that telemedicine interventions
can improve patient outcomes by facilitating remote glycemic
monitoring, patient–provider communication, and glycemic
control.5–9 However, multiple factors can influence the suc-
cess of telemedicine interventions. The use of specialized
telemedicine devices shows high attrition rates due to user
frustration and high device costs.10,11 Advancing age, low
socioeconomic status, and low health literacy impair the
ability to use new technology effectively, resulting in overall
lower usage.12–18 Telemedicine modalities using short mes-
saging service (SMS) and phone calls are particularly ap-
pealing due to their ubiquity and standard integration into
cellular phones, with findings that 92% of those making less
than $30,000 own a cellular phone.10
EpxDiabetes is a SMS and phone call-based intervention
that allows for bidirectional patient–provider communication.
This closed-loop communication is important for achieving
glycemic control since many patients do not take action in















































response to high or low readings19 and may experience anx-
iety from uncontrolled blood glucose readings and infrequent
physician feedback.20 Barriers faced by other telemedicine
interventions include response burden for patients and effort
burden for physicians to provide real-time feedback.21
EpxDiabetes reduces these particular barriers by utilizing a
simple, widely used system, and triaging patient data to
prioritize physician action. Upon detecting a dysglycemic
event or trend from self-reported fasting blood glucose
(FBG), EpxDiabetes prompts the patient’s provider to follow-
up with the patient, allowing for concerted provider detec-
tion and early intervention.
We previously demonstrated the real-world effectiveness
of EpxDiabetes in lowering FBG and HbA1c in a community
health care system implementation.5 We have now conducted
a randomized controlled trial (RCT) to assess the efficacy of
EpxDiabetes in lowering FBG and HbA1c in patients with poor
glycemic control (HbA1c > 7%), comparing the intervention
group to our practice standard of care. In addition, we assessed





The IRB-approved 6-month RCT was conducted at a primary
care clinic in St. Louis, Missouri. Standard of care consists
of quarterly clinic visits and monthly provider calls from
pharmacists to assess and modify patients’ diabetes man-
agement plan.
We queried the clinic’s electronic medical record (EMR)
using ICD-9 and ICD-10 codes (250.x) and medication lists for
patients with noninsulin-dependent T2DM seen within 18
months before the trial start date. Eligible patients were older
than the age of 18 years and had a most recent HbA1c value of
>7%. Patients were excluded from the trial if they did not have
access to a mobile phone or landline, participated in previous
implementations of EpxDiabetes, or were not currently
monitored by the pharmacists.
Subjects meeting selection criteria were consented and re-
cruited via phone from March to June 2016 on a rolling basis
by independent research staff. Three hundred twenty-five
(325) out of 346 eligible patients met enrollment criteria, 203
were successfully contacted, and 65 consented. Participants
were allocated in a 1:1 ratio to intervention and control
arms using simple randomization via the integrated function
within the epx.wustl.edu platform. For each patient, a random
IEEE754 float point value in the interval of [0, 1] was gener-
ated via the ‘‘Math.random’’ function from JavaScript. If the
value was >0.5, then the patient was added to the control
group; otherwise, the patient was added to the intervention
group. Simple randomization assigned 33 subjects to the in-
tervention group, and 32 subjects to the control group (Fig. 1).
STUDY DESIGN AND INTERVENTION
EpxDiabetes is based on an existing telemedicine platform,
Epharmix, and customized for diabetes care as outlined in
Peters et al.5 by allowing for collection of FBG. Being mindful
of limited health literacy requiring interventions with simple,
easy-to-read instructions, all EpxDiabetes messages are
designed at a fourth grade level as determined by the Flesch-
Kincaid Grade Level formula and calculated on the Read-
able.io website. Text messages and phone calls were provided
free of charge (excluding standard messaging rates) to pa-
tients on any network to further promote accessibility among
low socioeconomic populations.
Patients self-report FBG values by responding to automated
phone calls or SMS messages (Fig. 2). FBG values >400 or
<70 mg/dL trigger an automated alert via text or phone call to
the provider for a possible acute event, and the platform issues
an automated instruction directly to patients to contact their
providers and/or call 911 in an emergency. The algorithm
recognizes hyperglycemic trends and notifies providers if bi-
monthly average FBG exceeds 160 mg/dL. The Smart Sche-
duler modifies message frequency based on FBG to minimize
message fatigue; patients reporting euglycemia receive mes-
sages less frequently.
The intervention group received messages an average of
three times per week (twice a week to three times a day), de-
pending on FBG stability. The control group received mes-
sages three times during the first week to establish a FBG
baseline and once weekly thereafter without modifications
from the Smart Scheduler. The control group did not receive
any provider-initiated follow-up based on the self-reported
FBG data, however, they were instructed to call their provider
or 911 if severely dysglycemic and continue to receive stan-
dard of care.
DATA GATHERING AND ANALYSIS
Demographic data were obtained from patients at the time
of enrollment. Group differences were evaluated with a two-
tailed t-test (a = 0.05).
Pretrial, our primary outcomes were change in HbA1c and
change in FBG. Secondary outcomes were response rate and
engagement rate. Details on how each of these were calculated
can be found below.
We included only those patients who had obtained a
baseline HbA1c (within 3 months before enrolment into the
IMPROVING HBA1C WITH EPXDIABETES: AN RCT















































Fig. 2. EpxDiabetes intervention design and Alert protocol. Adapted from Peters et al.,5 a concomitant quality improvement trial using
EpxDiabetes.
Fig. 1. CONSORT diagram. Color images are available online.















































trial) and a posttrial HbA1c (within 4–8 months after enrol-
ment into the trial) in our analysis for HbA1c to evaluate a
direct glycemic effects of SMS intervention. HbA1c values
were extracted from the EMR 6 months after trial start date for
each patient. DHbA1c from baseline to posttrial was calcu-
lated. An intention to treat analysis was performed for patients
who did not respond through 6 months, but who did have
HbA1c measurements. A subgroup analysis was performed for
patients with baseline HbA1c >8%.
Baseline FBG for each patient was calculated by averaging
the first three patient-reported FBG values. To account for the
variable weekly message frequency, monthly FBG was de-
termined for each patient by averaging four consecutive
weekly FBG averages. The group average monthly DFBG was
calculated for the two groups.
Deidentified patient engagement data and response rates were
obtained from the Epharmix database. Patient monthly engage-
ment rate was defined as the proportion of patients responding
to at least 25% of texts or calls over 4 weeks. Average group
monthly engagement was calculated. Patient response rate was
the proportion of sent SMS messages or phone calls responded to.
Multiple linear regressions predicting DHbA1c and DFBG
after 6 months was found using backward elimination and
interpreted using adjusted R2. Data analysis was performed
using Microsoft Excel 2016 (2016; Microsoft, Redmond, WA),
PRISM (2016; GraphPad Software, La Jolla, CA), and SPSS
(2016; IBM Corp, Armonk, NY).
Results
BASELINE PATIENT CHARACTERISTICS
African Americans represent the majority in both groups. The
median income was $14,440 for the intervention group and
$12,600 for the control group. The demographic differences
between intervention and control groups were nonsignificant
(p > 0.05) (Table 1). There were no significant differences in the
distribution of specific comorbidities, other than lung disease,
nor in number of comorbidities between the intervention group
and control group (Table 1).
HBA1C AND FBG ANALYSIS
Pretrial and posttrial HbA1c were available for 19 patients in
the intervention group and 18 patients in the control group
due to missing the appointment within 4–8 months after en-
rollment into the trial; 29 out of 37 patients had a baseline
HbA1c >8%. On average, patients obtained their posttrial
HbA1c values 6 months after start of messages (181 days for
intervention, 186 days for control). Patients were enrolled
with an indefinite endpoint, outcomes were assessed at 6
months after enrolment.







Male 12 (37.5%) 8 (25%)
Female 20 (62.5%) 24 (75%)
Age
Average – SEM 54.6 – 1.82 55.34 – 1.94
Race
Caucasian 6 (18%) 2 (7%)
African American 27 (82%) 29 (93%)
Disability status
Disableda 19 (58%) 20 (63%)
Nondisabled 14 (42%) 12 (37%)
Education
No formal education 0 (0%) 0 (0%)
Grade school 1 (3%) 1 (3%)
Some high school 4 (12%) 10 (31%)
High school graduate 11 (33%) 10 (31%)
Some college 13 (39%) 7 (22%)
College graduate or beyond 4 (12%) 4 (13%)
Income
Mean – SEM $18,993 – 3,843 $16,525 – 2,125
Median $14,440 $12,600
Comorbidities
Hypertension 26 (79%) 25 (78%)
Lung diseaseb 6 (18%) 14 (44%)
Heart disease 2 (6%) 6 (19%)
Thyroid disease 2 (6%) 5 (16%)
Neurological disease 1 (3%) 3 (9%)
Cancer 3 (9%) 2 (6%)
Other 9 (27%) 10 (31%)
No. of comorbidities
0 5 (15%) 4 (13%)
1 15 (45%) 11 (34%)
2 5 (15%) 7 (21%)
3 6 (19%) 4 (13%)
4 1 (3%) 4 (13%)
5+ 1 (3%) 2 (6%)
aReceiving disability pay.
bp < 0.05 between groups.
SEM, standard error of the mean.
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Average HbA1c in the intervention group was 9.80%
(standard error of the mean [SEM] = 0.45%, n = 19) at baseline
and decreased to 9.11% (DHbA1c = -0.69%, SEM = 0.34%,
p = 0.055) posttrial. Average HbA1c in the control group was
9.23% (SEM = 0.32, n = 18) at baseline and barely decreased
posttrial to 9.20% (DHbA1c = -0.03%, SEM = 0.40, p = 0.946).
Baseline HbA1c was not significantly different between groups
( p = 0.31).
Patients in the intervention group with baseline HbA1c >8%
(n = 13) had a statistically significant decrease in HbA1c from
10.92% at baseline to 9.75% posttrial (DHbA1c = -1.17%,
SEM = 0.33, p = 0.004), while those in the control group with
baseline HbA1c >8% (n = 16) had a nonsignificant decrease
from 9.46% at baseline to 9.44% posttrial (DHbA1c = -0.02%,
SEM = 0.46, p = 0.957) (Fig. 3).
Patient-reported FBG was retrieved from the Epharmix
system and only patients who responded throughout 6 months
were analyzed. Average FBG in the intervention group was
172.5 mg/dL (SEM = 12.3 mg/dL, n = 17) at baseline and de-
creased to 150.9 mg/dL (DFBG -21.6 mg/dL, SEM = 7.5 mg/dL,
p = 0.01) posttrial. Average FBG in the control group was
191.1 mg/dL (SEM = 17.1 mg/dL, n = 16) at baseline and in-
creased posttrial to 204.1 mg/dL (DFBG +13.0 mg/dL, SEM =
28.5 mg/dL, p = 0.65). Baseline FBG was not significantly
different between groups ( p = 0.38). These results are consis-
tent with our HbA1c changes from baseline in the intervention
group.
At baseline, all patients in the study had HbA1c >7%.
Posttrial, 11% of patients in the intervention group had HbA1c
<7%, while none did in the control group (Fig. 4). In the in-
tervention group, 63% of patients had HbA1c >9%, which
decreased to 47% posttrial (Fig. 4). Changes of this magnitude
were not seen in the control group (50–44% with HbA1c >9%).
Correspondingly, at baseline, 63% of the intervention group
had FBG above 150 mg/dL, which reduced to 32% posttrial
(Fig. 4). The control group had 67% with FBG above 150 mg/
dL at baseline, which decreased slightly to 56% posttrial
(Fig. 4).
RESPONSE RATE
Response rate was defined as the absolute proportion of
total text messages or calls responded to. The overall average
response rate for the entire duration of the trial was 64.9% for
the control group and 63.6% for the intervention group
(Fig. 5).
ENGAGEMENT RATE
Engagement rate was defined as the proportion of partici-
pants who responded to at least 25% of SMS or phone calls
over 4 weeks. The average engagement rate was 48% for the
control group (95% confidence interval [CI], 0.296–0.621) and
58% for the intervention group (95% CI, 0.373–0.627) (Fig. 5).
MULTIPLE LINEAR REGRESSION ANALYSIS:
DEMOGRAPHIC FACTORS PREDICTING
CHANGES IN DHBA1C
Multiple linear regressions were calculated to predict
DHbA1c at the end of the 6-month trial based on baseline
DHbA1c, education, smoking status, income, age, number of
comorbidities, and response rate (Table 2). Significant pre-
dictors of intervention DHbA1c were smoking status, number
of comorbidities, and response rate. In contrast, the only
significant predictor of control DHbA1c was baseline HbA1c.
Significant predictors of intervention DFBG were baseline
FBG and smoking status. There were no significant predictors
of control DFBG.
Discussion
As the prevalence of diabetes continues to rise, it is essential
to develop and implement cost-effective therapeutic strategies
to achieve glycemic control. Current methods are less effective
for the 30.9–33.4% of adults in the United States who are
above target HbA1c levels.
3,22 Our study shows a statistically
significant HbA1c reduction of 1.17% for patients in the in-
tervention group with baseline HbA1c >8% by using SMS and
phone-based interventions that allow for bidirectional pa-
tient–provider communication. This change in HbA1c was
supported by a significant decrease in self-reported average
FBG, half of patients with baseline FBG >150 mg/dL getting
below 150 mg/dL posttrial, and a 11% increase in the amount
of patients with well-controlled diabetes (HbA1c <7%) in the
intervention group. This is clinically significant because
Fig. 3. Comparison of intervention and control group DHbA1c after
6 months.
XU ET AL.















































standard therapies for T2DM, which include oral anti-
hyperglycemic agents, are known to lower HbA1c by 0.5–
1.25%.23 Our nonpharmacologic, low-cost, and low-risk
intervention complements standard pharmacologic therapies
by further reducing HbA1c by a comparable amount. While it
has been demonstrated that the lowest risk of complications is
achieved when patients can lower their HbA1c to <6%, it is also
clear that any reduction from baseline HbA1c can be beneficial
in risk reduction.24
Smoking status was a significant predictor of HbA1c and
FBG changes. Those who never smoked saw greater decreases
in HbA1c and FBG than former and current smokers. These
findings correlate with previous studies demonstrating that
smoking exacerbates insulin resistance and the micro- and
Fig. 4. Distribution of the intervention and control groups across HbA1c values and FBG values from baseline to posttrial. FBG, fasting blood
glucose. Color images are available online.
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macrovascular complications of T2DM.25 Response rate was a
significant predictor of HbA1c in the intervention group, but
not in the control group. This difference is likely due to the
greater messaging frequency and the bidirectional commu-
nication between patients and providers experienced by the
intervention group. Greater response rate to the intervention
was associated with decreases in HbA1c.
The engagement rate was high for both the intervention
group (58%) and control group (48%). While definitions of
engagement vary, in similar studies, the proportion of people
ever using an intervention ranged from 28% to 53%.26,27 In-
terestingly, the intervention group, which received more mes-
sages relative to the control group, showed higher response and
engagement rates after 6 months of intervention. However, the
response rate was a nonsignificant predictor of changes in FBG.
Higher response rates were correlated with increases in FBG.
This may seem to contradict the effectiveness of EpxDiabetes,
but patients with FBG instability receive additional messages by
platform design, and higher FBG may trigger increased en-
gagement with the system due to concerns about glycemic
control. Patients are more likely to enroll in and engage with
telemedicine interventions when it is perceived to be benefi-
cial.28–30 Patients are less likely to consider an intervention
beneficial when their blood glucose seems to be in control.30,31
Fig. 5. The average response rates and average engagement rates for each month of intervention. Standard error bars are displayed.
*Response rates were significantly different during months 5 and 6. Color images are available online.
XU ET AL.















































At baseline, the intervention group had a lower response
rate. This may reflect the heavier message burden before the
Smart Scheduler reduced the frequency of messages based on
FBG stability. We believe that the bidirectional patient–
provider communication the intervention group received
encourages greater response and engagement rates compared
to the control group without physician feedback. Macdonald
et al.12 noted that diabetes telemedicine interventions allow
for timely physician feedback, which increases patient per-
ceptions of intervention usefulness, increasing usage, and
engagement. Bidirectional communication can encourage
engagement by increasing feelings of connectivity between
patients and their health care providers.32,33 The higher en-
gagement rate of the intervention group demonstrates the
ability of EpxDiabetes to facilitate high engagement over
long periods of time.
This intervention is a scalable and effective way of man-
aging large numbers of patients and optimizing response to
patient needs. In a previous study, EpxDiabetes was im-
plemented as a single-arm quality improvement project across
community clinics in St. Louis, Missouri, and managed 314
patients.5 EpxDiabetes gives actionable data to providers,
enabling providers to follow-up and adjust treatment plans,
and then to receive real-time feedback on those changes. We
believe that this RCT is an appropriate ancillary study to fol-
low up implementation of EpxDiabetes in a community set-
ting in a more rigorous research setting.
Limitations to this study relate to sample size and
scheduling for follow-up. As a result of low sample size, the
trial had low power to detect significant changes in the
intervention arm. In addition, a larger, more diverse study
sample is needed to better understand differences in inter-
vention effectiveness. Our study population reflected the
patient population of our city, so generalizability would
improve with a larger national or global trial.
We did not track the antihyperglycemic therapies or lifestyle
interventions that the patient groups were given since it was
assumed that they were on optimal medical therapy and care
plan. In addition, since there were no differences in charac-
teristics between the intervention and control groups at base-
line, we are reasonably confident that any changes in FBG or
HbA1c as a result of lifestyle or medication adherence changes
can be attributed to aspects of our intervention. However, we
acknowledge that it is important to identify which, if any,
standard medical therapies or lifestyle interventions, such as
diet or exercise, may have better complementarity to tele-
medicine. This will enable us to further tailor and individualize
EpxDiabetes to patients on particular therapy plans. We will
Table 2. Demographic and Socioeconomic Factors Predicting Changes in HbA1c
INDEPENDENT VARIABLE
INTERVENTION DHBA1C CONTROL DHBA1C INTERVENTION FBG CONTROL FBG
COEFFICIENT COEFFICIENT COEFFICIENT COEFFICIENT
Baseline HbA1c -0.756a — —
Baseline FBG — — -0.265a -0.378
Education -0.649
Smoking status -0.929a -28.920a
Income (thousands) 0.004 0.000 1.00 1.00
Age -0.066
No. of comorbidities -0.635a
Response rate -2.595a 31.205 245.878
Constant 2.551 9.918 24.883 -113.875
R2adj 0.669 0.302 0.598 0.248
F-ratio 7.062a 2.512 5.459a 2.207
n 19 18 17 16
A higher value for smoking status indicates less smoking.
ap < 0.05.
FBG, fasting blood glucose.
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make every effort to include collection and analysis of these
data in future studies.
Finally, not every patient was able to obtain HbA1c
measurements that corresponded to an end-of-trial mea-
surement, which results in a limitation to our sample size
and a possible bias from self-selection of patients who
prioritized management of their T2DM. We believe that this
highlights the disparities in access to care and transporta-
tion barriers in our community, further emphasizing the
need for a telemedicine tool in communities such as ours. In
future studies, it will be beneficial to schedule both pretrial
and posttrial measurements to ensure more patients meet
the criteria for analysis. Finally, we recommend examining
patient satisfaction to address barriers to engaging with the
system.
Conclusion
EpxDiabetes is an effective telemedicine intervention that
facilitates glycemic control for patients with T2DM, especially
with baseline HbA1c >8%. It is low-cost, accessible, and fa-
cilitates high engagement for patients of different ages, health
literacy, and socioeconomic levels.
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